Patents Assigned to Intrexon Corporation
-
Publication number: 20190016765Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.Type: ApplicationFiled: June 21, 2018Publication date: January 17, 2019Applicant: Intrexon CorporationInventor: Thomas D. REED
-
Publication number: 20180344876Abstract: This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.Type: ApplicationFiled: May 31, 2018Publication date: December 6, 2018Applicant: Intrexon CorporationInventors: Jeremiah F. ROETH, Charles C. REED, Brandon CUTHERTSON, Sunil CHADA, William E. FOGLER, Fayaz KHAZI
-
Publication number: 20180348231Abstract: The invention relates to a novel ligand inducible polypeptide coupling system and methods of modulating cell signal transduction pathways and other intracellular and extracellular protein-protein interactions.Type: ApplicationFiled: March 29, 2016Publication date: December 6, 2018Applicant: Intrexon CorporationInventors: Daniel Paul BEDNARIK, Charles REED, Vinodh KURELLA
-
Publication number: 20180333486Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.Type: ApplicationFiled: May 24, 2018Publication date: November 22, 2018Applicant: Intrexon CorporationInventors: Robert P. Beech, Thomas D. Reed
-
Patent number: 10131916Abstract: The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the Agaricus bisporus lectin gene. The sequences drive expression preferentially to fruit body tissue. A method for expressing a nucleotide sequence in fungi using the regulatory sequences disclosed herein is provided. The method comprises transforming a fungal cell to comprise a nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed fungus from the transformed cell.Type: GrantFiled: September 11, 2015Date of Patent: November 20, 2018Assignee: Intrexon CorporationInventors: Zhixin Shi, Jack Q. Wilkinson, Donald S. Walters, C. Peter Romaine
-
Patent number: 10087231Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel nuclear receptors comprising a substitution mutation and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene within a host cell using this inducible gene expression system.Type: GrantFiled: December 17, 2015Date of Patent: October 2, 2018Assignee: Intrexon CorporationInventors: Subba Reddy Palli, Marianna Zinovievna Kapitskaya
-
Patent number: 10081817Abstract: The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phaType: GrantFiled: October 31, 2016Date of Patent: September 25, 2018Assignee: Intrexon CorporationInventor: Malla Padidam
-
Patent number: 10046049Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.Type: GrantFiled: September 26, 2016Date of Patent: August 14, 2018Assignee: Intrexon CorporationInventors: Robert P. Beech, Thomas D. Reed
-
Patent number: 10036026Abstract: A method for using cloning vector plasmids to produce DNA molecules, such as transgenes, in a single cloning step. The transgenes can be used for the purpose of gene expression or analysis of gene expression. The plasmid cloning vectors are engineered to minimize the amount of manipulation of DNA fragment components by the end user of the vectors and the methods for their use. Transgenes produced using the invention may be used in a single organism, or in a variety of organisms including bacteria, yeast, mice, and other eukaryotes with little or no further modification.Type: GrantFiled: August 13, 2015Date of Patent: July 31, 2018Assignee: Intrexon CorporationInventor: Thomas D. Reed
-
Publication number: 20180140721Abstract: The invention provides polynucleotides, vectors and viruses expressing frataxin and methods of treating Friedreich's Ataxia.Type: ApplicationFiled: November 8, 2017Publication date: May 24, 2018Applicant: Intrexon CorporationInventors: Stephen SCHAUER, Darby THOMAS, Gregory ROBINSON, Mark PYKETT, Richard THORN, Kirsten GRUIS
-
Publication number: 20180126007Abstract: The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.Type: ApplicationFiled: June 29, 2017Publication date: May 10, 2018Applicant: Intrexon CorporationInventors: Bethany Lynn MERENICK, Robert P. Beech, Thomas D. Reed, Anna P. Tretiakova, Richard E. Peterson
-
Patent number: 9944659Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.Type: GrantFiled: September 16, 2015Date of Patent: April 17, 2018Assignee: INTREXON CORPORATIONInventors: Ray A. James, Sheela K. Chellappan, Robert E. Hormann
-
Publication number: 20180079759Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.Type: ApplicationFiled: November 17, 2016Publication date: March 22, 2018Applicant: Intrexon CorporationInventors: Sheela K. CHELLAPPAN, Robert E. Hormann, Inna Shulman
-
Publication number: 20180002719Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.Type: ApplicationFiled: July 13, 2017Publication date: January 4, 2018Applicant: Intrexon CorporationInventors: Jeremiah F. ROETH, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler
-
Publication number: 20170335351Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.Type: ApplicationFiled: July 13, 2017Publication date: November 23, 2017Applicant: INTREXON CORPORATIONInventors: William J. COLEMAN, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban
-
Publication number: 20170312315Abstract: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.Type: ApplicationFiled: May 10, 2017Publication date: November 2, 2017Applicants: Intrexon Corporation, University of Pittsburgh-Of The Commonwealth System Of Higher EducationInventors: Mark BRAUGHLER, Prasanna Kumar, Walter J. Storkus, Hideho Okada
-
Patent number: 9802936Abstract: This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.Type: GrantFiled: October 9, 2007Date of Patent: October 31, 2017Assignee: Intrexon CorporationInventors: Colin M. Tice, Enrique L. Michelotti, Robert E. Hormann
-
Publication number: 20170275600Abstract: Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.Type: ApplicationFiled: April 6, 2017Publication date: September 28, 2017Applicant: Intrexon CorporationInventors: Timothy David Jones, Francis Joseph Carr
-
Publication number: 20170260244Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.Type: ApplicationFiled: March 6, 2017Publication date: September 14, 2017Applicant: Intrexon CorporationInventor: Thomas D. REED
-
Patent number: 9745603Abstract: Multi-carbon compounds such as ethanol, n-butanol, sec-butanol, isobutanol, tert-butanol, fatty (or aliphatic long chain) alcohols, fatty acid methyl esters, 2,3-butanediol and the like, are important industrial commodity chemicals with a variety of applications. The present invention provides metabolically engineered host microorganisms which metabolize methane (CH4) as their sole carbon source to produce multi-carbon compounds for use in fuels (e.g., bio-fuel, bio-diesel) and bio-based chemicals. Furthermore, use of the metabolically engineered host microorganisms of the invention (which utilize methane as the sole carbon source) mitigate current industry practices and methods of producing multi-carbon compounds from petroleum or petroleum-derived feedstocks, and ameliorate much of the ongoing depletion of arable food source “farmland” currently being diverted to grow bio-fuel feedstocks, and as such, improve the environmental footprint of future bio-fuel, bio-diesel and bio-based chemical compositions.Type: GrantFiled: June 24, 2016Date of Patent: August 29, 2017Assignee: Intrexon CorporationInventors: William J. Coleman, Genevieve M. Vidanes, Guillaume Cottarel, Sheela Muley, Roy Kamimura, Akbar F. Javan, Jianping Sun, Eli S. Groban